newsfilter
← Latest News
PR Newswire·

TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

EDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and